US FDA Regulations for Novel and Innovative Products
有任何问题？向我们的专家获取相关信息
联系我们
Ready to sell your novel device in the United States? In a system based on predicate devices and substantial equivalence, marketing an innovative or novel device comes with some unique challenges. What do you do when your innovative device has no predicate?
As the range of novel and innovative medical devices continues to grow, the challenge for both industry and the US FDA is to determine the best way to get these new devices to health care providers and patients as soon as possible, while ensuring safety and effectiveness. In this whitepaper, we discuss your options for bringing your novel device to the US market.
What you will learn in this 7-page white paper:
- What are the common regulatory pathways in the US?
- What does novel mean?
- What to do if your device is truly novel?
- What is the de novo process?
- What is humanitarian device exemption (HDE)?
- What is the expedited access pathway (EAP)?
Get answers to all of these questions and more in this white paper.
About the Author
Audrey Swearingen, RAC (US): Audrey Swearingen is Director of Regulatory Affairs at Emergo's Austin, Texas headquarters. With over 20 years of experience in regulatory affairs, Audrey's areas of expertise include US FDA medical device registration, as well as European and Canadian device registration.
相关
-
美国FDA eSTAR电子递交模板与资源要求解析
自2018年起，美国食品和药物管理局（U.S. Food and Drug Administration，FDA）开始试行以电子化方式来帮助行业提供完整的510(k)上市前通知。2022年，为推进以电子格式提供510(k)递交文件的过渡，美国FDA正式发布关于使用电子递交模板和资源的最终指导文
阅读更多 -
了解欧盟新的医疗器械法规 - MDR 2017/745
您可能已经听说，欧盟完善的医疗器械法规即将迎来变化。并且您可能有很多疑问。这些变化意味着什么，它们将如何影响您的公司？ 欧盟新的医疗器械法规（MDR）将对医疗器械制造商进入欧盟市场的方式以及如何在产品的整个生命周期内维持合规产生重大影响。在这份长达28页的白皮书中，Emergo的
阅读更多